DDR1 and melanoma: In line with this notion, we found that DNA amplification and elevated mRNA levels of DDR1 negatively correlated to the activity of BRAF and MEK inhibitors in melanoma cell lines from the GDSC (Genomic of Drug Sensitivity in Cancer) (Appendix Fig S5).